MetLife will try to persuade a federal judge Wednesday that it shouldn’t be designated a “systemically important financial institution,” in the first court hearing of a case with potential either to curtail or to solidify the law’s reach.
The Patent and Trademark Office is gearing up to rule nearly 13 years after Coke first tried to register “zero” in the U.S., triggering a challenge from Dr Pepper Snapple Group, which also has a diet drink named Zero.
President Barack Obama’s $4.1 trillion budget proposal is designed to find a few spots of bipartisan agreement while also laying out a broader liberal policy agenda for a potential future Democratic administration.
An advisory panel to the FDA voted to recommend the agency approve the sale of a knockoff version of J&J’s arthritis drug Remicade, which had U.S. sales of $4.45 billion last year. The copy was developed by Celltrion and licensed to Pfizer.
French drugmaker Sanofi has ended a licensing pact with MannKind for the rights to sell Afrezza, saying the insulin inhaler for diabetes care was unlikely to reach even the lowest patient levels anticipated.